TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.
| Revenue (Most Recent Fiscal Year) | $329.00M |
| Net Income (Most Recent Fiscal Year) | $23.38M |
| PE Ratio (Current Year Earnings Estimate) | 39.80 |
| PE Ratio (Trailing 12 Months) | 148.79 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 14.67 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 23.89 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 297.68 |
| Pre-Tax Margin (Trailing 12 Months) | 10.80% |
| Net Margin (Trailing 12 Months) | 10.13% |
| Return on Equity (Trailing 12 Months) | 18.88% |
| Return on Assets (Trailing 12 Months) | 7.05% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.02 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.04 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.03 |
| Inventory Turnover (Trailing 12 Months) | 0.45 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.49 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.03 |
| Earnings per Share (Most Recent Fiscal Year) | $0.15 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.24 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 158.76M |
| Free Float | 141.86M |
| Market Capitalization | $5.67B |
| Average Volume (Last 20 Days) | 2.74M |
| Beta (Past 60 Months) | 2.21 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.64% |
| Percentage Held By Institutions (Latest 13F Reports) | 58.58% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |